ES2118457T3 - Derivados de piridina, composiciones farmaceuticas que comprenden los mismos, el uso de los mismos para la fabricacion de medicamentos que tienen valor terapeutico o preventivo, y un proceso para preparar los mismos. - Google Patents

Derivados de piridina, composiciones farmaceuticas que comprenden los mismos, el uso de los mismos para la fabricacion de medicamentos que tienen valor terapeutico o preventivo, y un proceso para preparar los mismos.

Info

Publication number
ES2118457T3
ES2118457T3 ES95102165T ES95102165T ES2118457T3 ES 2118457 T3 ES2118457 T3 ES 2118457T3 ES 95102165 T ES95102165 T ES 95102165T ES 95102165 T ES95102165 T ES 95102165T ES 2118457 T3 ES2118457 T3 ES 2118457T3
Authority
ES
Spain
Prior art keywords
group
same
derivatives
alkyl
piridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95102165T
Other languages
English (en)
Inventor
Shigeru Souda
Norihiro Ueda
Shuhei Miyazawa
Katsuya Tagami
Seiichiro Nomoto
Makoto Okita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27283658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2118457(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ES2118457T3 publication Critical patent/ES2118457T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCION SUMINISTRA DERIVADOS DE LA PIRIDINA REPRESENTADOS POR LA FORMULA GENERAL (I) EN DONDE R1 Y R2 PUEDEN SER IGUALES O DIFERENTES ENTRE SI Y CADA UNA REPRESENTA UN ATOMO DE HIDROGENO, UN GRUPO DE ALQUILO C1-C6, DE ALCOXI C1-C6, DE ALQUILO C1-C6 HALOGENADO, DE ALCOXI(C1-C6)CARBONILO O DE CARBONILO O UN ATOMO DE HALOGENO; X REPRESENTA UN GRUPO REPRESENTADO POR LA FORMULA -O-, -SUN ATOMO DE HIDROGENO O UN GRUPO DE ALQUILO C1-C6, FENILO, BENCILO O ALCOXI(C1-C6)CARBONILO); Z REPRESENTA (1) UN GRUPO REPRESENTADO POR LA FORMULA GENERAL: -O(CH2)QR5 EN DONDE Q REPRESENTA UN ENTERO ENTRE 1 Y 3 Y R5 REPRESENTA UN GRUPO DE NAFTIL QUE PUEDE ESTAR SUSTITUIDO CON UN GRUPO DE ALCOXIDO C1-C6, UN GRUPO HIDROXILO O UN ATOMO DE HALOGENO; UN GRUPO PIRIDILO O UN GRUPO DE FURILO, (2) UN GRUPO REPRESENTADO POR LA FORMULA -OR9 EN DONDE OR9 REPRESENTA UN GRUPO DE FENILO, TOLILO, XILILO O NAFTILO, N REPRESENTA UN ENTERO ENTRE 0 Y 2; M REPRESENTA EN ENTERO ENTRE 2 Y 10; Y J Y K PUEDEN SER IGUALES O DIFERENTESENTRE SI Y CADA UNA DE ELLAS REPRESENTA UN ATOMO DE HIDROGENO O UN GRUPO DE ALQUILO C1-C6, ASIMISMO SE PRESENTAN LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS COMPUESTOS. TAMBIEN SE SUMINISTRAN COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN ESTOS DERIVADOS JUNTO CON EL USO DE LOS DERIVADOS PARA LA MANUFACTURA DE MEDICAMENTOS QUE TIENEN VALOR TERAPEUTICO O PREVENTIVO EN EL TRATAMIENTO DE ULCERAS PEPTICAS. TAMBIEN SE SUMINISTRAN PROCESOS PARA PREPARAR DICHOS DERIVADOS DE LA PIRIDINA.
ES95102165T 1986-11-13 1987-11-13 Derivados de piridina, composiciones farmaceuticas que comprenden los mismos, el uso de los mismos para la fabricacion de medicamentos que tienen valor terapeutico o preventivo, y un proceso para preparar los mismos. Expired - Lifetime ES2118457T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP27053686 1986-11-13
JP2198987 1987-02-02
JP7778487 1987-03-31

Publications (1)

Publication Number Publication Date
ES2118457T3 true ES2118457T3 (es) 1998-09-16

Family

ID=27283658

Family Applications (3)

Application Number Title Priority Date Filing Date
ES95102165T Expired - Lifetime ES2118457T3 (es) 1986-11-13 1987-11-13 Derivados de piridina, composiciones farmaceuticas que comprenden los mismos, el uso de los mismos para la fabricacion de medicamentos que tienen valor terapeutico o preventivo, y un proceso para preparar los mismos.
ES91117132T Expired - Lifetime ES2112260T3 (es) 1986-11-13 1987-11-13 Derivados de piridina, composiciones farmaceuticas que comprenden los mismos, su utilizacion en la fabricacion de medicamentos que tienen valor terapeutico o preventivo y procedimiento para su fabricacion.
ES87116797T Expired - Lifetime ES2061471T5 (es) 1986-11-13 1987-11-13 Derivados de la piridina, compuestos farmaceuticos que comprenden la misma, su utilizacion para la fabricacion de medicamentos con valor terapeutico o preventivo y procedimiento para su fabricacion.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES91117132T Expired - Lifetime ES2112260T3 (es) 1986-11-13 1987-11-13 Derivados de piridina, composiciones farmaceuticas que comprenden los mismos, su utilizacion en la fabricacion de medicamentos que tienen valor terapeutico o preventivo y procedimiento para su fabricacion.
ES87116797T Expired - Lifetime ES2061471T5 (es) 1986-11-13 1987-11-13 Derivados de la piridina, compuestos farmaceuticos que comprenden la misma, su utilizacion para la fabricacion de medicamentos con valor terapeutico o preventivo y procedimiento para su fabricacion.

Country Status (18)

Country Link
US (3) US5045552A (es)
EP (3) EP0654471B1 (es)
JP (1) JP2544567B2 (es)
KR (1) KR910003330B1 (es)
CN (1) CN1018923B (es)
AT (2) ATE168111T1 (es)
AU (1) AU594836B2 (es)
CA (1) CA1265138A (es)
DE (4) DE19975035I2 (es)
DK (2) DK171024B1 (es)
ES (3) ES2118457T3 (es)
FI (1) FI90544C (es)
HK (1) HK194296A (es)
HU (1) HU198475B (es)
LU (1) LU90396I2 (es)
NL (1) NL990015I2 (es)
NO (2) NO170932C (es)
NZ (1) NZ222488A (es)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62201884A (ja) * 1986-02-28 1987-09-05 Tokyo Tanabe Co Ltd ベンズイミダゾール誘導体及びその製造法
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
AT391693B (de) * 1988-11-15 1990-11-12 Cl Pharma Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer
US5294629A (en) * 1988-11-22 1994-03-15 Meiji Seika Kaisha, Ltd. Benzothiazole and benzimidazole derivatives and antiulcer agent containing the same
SE8804629D0 (sv) * 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
IE64199B1 (en) * 1988-12-22 1995-07-12 Haessle Ab Compound with gastric acid inhibitory effect and process for its preparation
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
US5049674A (en) * 1989-12-20 1991-09-17 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
ES2024357A6 (es) * 1990-12-05 1992-02-16 Genesis Para La Investigacion Procedimiento de obtencion de halohidrato de 2-halometil-3,5-dimetil-4-metoxipiri-dina.
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
US5504082A (en) * 1992-06-01 1996-04-02 Yoshitomi Pharmaceutical Industries, Ltd. Pyridine compound and pharmaceutical compostions
EP0585722B1 (en) * 1992-08-21 1996-05-15 Eisai Co., Ltd. Benzimidazole derivatives as antimicrobal agent against Campylobacter pylon
CA2156258A1 (en) * 1993-02-17 1994-09-01 Bernhard Kohl Substituted heteroarylalkylthiopyridines for controlling helicobacter bacteria
DK0706523T3 (da) * 1993-06-29 2001-06-18 Byk Gulden Lomberg Chem Fab Substituerede arylthioalkylthiopyridiner
TW280770B (es) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
EP0729957A4 (en) * 1993-10-29 1996-12-27 Yoshitomi Pharmaceutical PYRIDE DERIVATIVES AND THEIR MEDICAL USE
KR0142815B1 (ko) * 1994-12-02 1998-07-15 정도언 신규한 5-피롤릴-6-할로게노-2피리딜메틸설피닐벤즈이미다졸 유도체
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
KR970032861A (ko) * 1995-12-29 1997-07-22 김준웅 헬리코박터 피로리 제거용 약제 투여방법
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6051570A (en) * 1997-05-30 2000-04-18 Dr. Reddy's Research Foundation Benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
US6303644B1 (en) 1997-07-25 2001-10-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Proton pump inhibitor in therapeutic combination with antibacterial substances
US7230014B1 (en) 1997-10-14 2007-06-12 Eisai Co., Ltd. Pharmaceutical formulation comprising glycine as a stabilizer
PT1039905E (pt) * 1997-10-14 2006-11-30 Eisai Co Ltd Formulação farmacêutica que compreende glicina como um estabilizador
US6861448B2 (en) 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
JP2002509149A (ja) 1998-01-14 2002-03-26 ザ ユーエイビー リサーチ ファウンデイション 細菌ｎａｄシンテターゼ酵素の阻害剤の合成およびスクリーニング方法、その化合物、ならびに細菌ｎａｄシンテターゼ酵素の阻害剤を用いる細菌および微生物感染の治療方法
DE19815634A1 (de) * 1998-04-07 1999-10-14 Bayer Ag Verfahren zur Herstellung von 3-Methoxy-1-propanol
CA2330324A1 (en) * 1998-04-30 1999-11-04 Sepracor Inc. S-rabeprazole compositions and methods
WO1999055157A1 (en) * 1998-04-30 1999-11-04 Sepracor Inc. R-rabeprazole compositions and methods
IE990506A1 (en) * 1998-06-26 2000-11-15 Russinsky Ltd Pyridine Building Blocks
TR200100431T2 (tr) 1998-08-10 2001-06-21 Partnership Of Michael E. Garst, George Sachs & Jai Moo Proton pompalama önleyici ilaçlar
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
WO2000009092A1 (en) 1998-08-12 2000-02-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
JP3926936B2 (ja) * 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6174902B1 (en) 1999-04-28 2001-01-16 Sepracor Inc. R-rabeprazole compositions and methods
JP4980527B2 (ja) 1999-06-07 2012-07-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性化合物を含有する新規の製剤および投与形
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6436939B2 (en) 2000-03-31 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists
EP1359912A4 (en) * 2000-06-19 2006-05-03 Eisai Co Ltd NEW METHODS USING PYRIDINE DERIVATIVES
US6544556B1 (en) * 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
AU2002234545A1 (en) 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
AU2002221939A1 (en) 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Rapidly disintegrating tablet comprising an acid-labile active ingredient
JP4241041B2 (ja) 2000-12-07 2009-03-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸分解性活性成分を含有するペースト形の医薬品製造物
NL1018295C2 (nl) * 2001-06-15 2002-12-17 Dsm Nv Werkwijze voor de bereiding van 4-chloor-pyridine-n-oxiden.
JP4020076B2 (ja) 2001-09-18 2007-12-12 ゼリア新薬工業株式会社 ベンズイミダゾール誘導体
AU2002365936A1 (en) * 2001-11-16 2003-09-02 Eisai Co. Ltd Compositions and methods to treat gastrointestinal disorders
SE0104295D0 (sv) * 2001-12-18 2001-12-18 Astrazeneca Ab New process
WO2003082858A1 (en) * 2002-03-26 2003-10-09 Dr. Reddy's Laboratories Limited Crystalline forms of rabeprazole sodium
WO2003097011A1 (en) * 2002-05-17 2003-11-27 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
AU2003254282A1 (en) * 2002-08-01 2004-02-23 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
AT413538B (de) * 2002-10-01 2006-03-15 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von substituierten pyridin-n-oxid-verbindungen
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
AU2003293749B2 (en) 2002-12-06 2009-12-24 Takeda Gmbh Process for preparing (S)-pantoprazole
ES2397380T3 (es) 2002-12-06 2013-03-06 Takeda Gmbh Procedimiento para preparar compuestos activos ópticamente puros
AU2003288576A1 (en) * 2002-12-16 2004-07-09 Ranbaxy Laboratories Limited Rabeprazole calcium
US7507829B2 (en) * 2002-12-19 2009-03-24 Teva Pharmaceuticals Industries, Ltd Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
US20060094762A1 (en) * 2003-01-07 2006-05-04 Yatendra Kumar Magnesium salt of imidazole derivative
US20040180935A1 (en) * 2003-02-28 2004-09-16 Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Inc. Crystalline form Z of rabeprazole sodium and process for preparation thereof
ES2245277T1 (es) * 2003-03-12 2006-01-01 Teva Pharmaceutical Industries Limited Solidos cristalinos y amorfos de pantoprazol y procedimientos para su preparacion.
US7608625B2 (en) * 2003-03-13 2009-10-27 Eisai R & D Management Co., Ltd. Method for treating bruxism and bruxism-related diseases
WO2004085424A1 (ja) 2003-03-24 2004-10-07 Eisai Co., Ltd. スルホキシド誘導体またはその塩のアモルファスの製造方法
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
WO2004101533A1 (en) * 2003-05-12 2004-11-25 Janssen Pharmaceutica, N.V. 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands
MXPA05013316A (es) * 2003-06-10 2006-03-17 Teva Pharma Proceso para preparar bencimidazoles 2[-(piridinil)metil]sulfinil-sustituidos y derivados clorados novedosos de pantoprazol.
EP2112920B1 (en) * 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
JP2007521314A (ja) * 2003-07-15 2007-08-02 アラーガン、インコーポレイテッド プロトンポンプ阻害薬の異性体純粋なプロドラッグを製造するための方法
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2007504261A (ja) * 2003-09-03 2007-03-01 エイジーアイ・セラピューティクス・リサーチ・リミテッド プロトンポンプ阻害剤製剤、並びに当該製剤を製造及び使用する方法関連出願の表示
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
WO2005077936A1 (en) 2004-02-11 2005-08-25 Ulkar Kimya Sanayii Ve Ticaret A.S. Pyridine benzimidazole sulfoxides with high purity
AU2005216863A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors
AU2005216862A1 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
WO2005107721A2 (en) * 2004-05-07 2005-11-17 Altana Pharma Ag Pharmaceutical dosage form comprising pellets as well as its manufacturing process
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP4884967B2 (ja) * 2004-06-30 2012-02-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンズイミダゾール誘導体塩沈殿物の製造方法
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
JP3921497B2 (ja) * 2004-08-06 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンズイミダゾール誘導体とアミンとの塩およびその製造方法
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006024890A1 (en) * 2004-08-30 2006-03-09 Apollo International Limited Improved process for rabeprazole sodium in amorphous form
CA2603290A1 (en) * 2004-09-30 2006-04-06 Jiangsu Hansen Pharmaceutical Co., Ltd. Prazole derivatives and salts thereof and use of same
CN100364989C (zh) * 2004-09-30 2008-01-30 江苏豪森药业股份有限公司 拉唑类衍生物及其盐和用途
KR20070109985A (ko) 2004-11-22 2007-11-15 아나디스 리미티드 생물활성 조성물
CA2606799C (en) 2005-02-21 2015-04-28 Cipla Limited Process for synthesis of proton pump inhibitors
MX2007011967A (es) * 2005-03-30 2007-12-10 Lupin Ltd Un proceso mejorado para la fabricacion de rabeprazol sodico.
US7601737B2 (en) 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
GB0525710D0 (en) * 2005-12-17 2006-01-25 Pliva Hrvatska D O O An improved process for preparing of substituted 2-benzimidazolesulfoxide compounds
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1818331A1 (en) 2006-02-14 2007-08-15 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Process for the preparation of 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole substantially free of sulfone impurity
PL2003130T3 (pl) 2006-03-10 2012-04-30 Link Genomics Inc Nowa pochodna pirydyny o aktywności przeciwko helicobacter pylori
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
KR100771655B1 (ko) * 2006-04-24 2007-10-30 주식회사 카이로제닉스 라베프라졸 및 그 중간체의 제조방법
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US7786309B2 (en) 2006-06-09 2010-08-31 Apotex Pharmachem Inc. Process for the preparation of esomeprazole and salts thereof
US7863330B2 (en) * 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
WO2008017020A2 (en) * 2006-08-03 2008-02-07 Dr. Reddy's Laboratories Limited Process for preparing proton pump inhibitors
WO2008036201A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2065379A4 (en) * 2006-10-13 2011-01-19 Eisai R&D Man Co Ltd BENZIMIDAZOLE HAVING INHIBITORY ACTIVITY OF GASTRIC ACID SECRETION
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
DK2103608T3 (da) 2006-12-18 2012-09-17 Arigen Pharmaceuticals Inc Helicobacter pylori eradikerende middel med inhiberende virkning på mavesyresekretion
ITMI20062449A1 (it) 2006-12-19 2008-06-20 Dipharma Spa Forma cristallina di rabeprazolo sodico
NZ598728A (en) 2006-12-22 2013-09-27 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
JP2010521453A (ja) * 2007-03-15 2010-06-24 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 新規プロドラッグ
WO2008146297A2 (en) * 2007-05-25 2008-12-04 Hetero Drugs Limited Improved process for amorphous rabeprazole sodium
US8247568B2 (en) * 2007-06-21 2012-08-21 Matrix Laboratories Ltd Process for the preparation of pure rabeprazole
EP2181106A1 (en) * 2007-07-17 2010-05-05 Ranbaxy Laboratories Limited Process for the preparation op pantoprazole sodium and pantoprazole sodium sesquihydrate
CN101497604B (zh) * 2008-01-30 2012-09-26 山东轩竹医药科技有限公司 含有被烷氧乙酰胺基氧基取代的吡啶的苯并咪唑衍生物
CN101497603B (zh) * 2008-01-30 2012-11-07 山东轩竹医药科技有限公司 含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物
SI22806A (sl) * 2008-06-23 2009-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove kristalinične oblike natrijevega rabeprazola
BRPI1014314A2 (pt) * 2009-04-09 2019-09-24 Arigen Pharmaceuticals Inc derivado de tiopiridina, e, composição farmacêutica.
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
WO2011004281A1 (en) 2009-07-09 2011-01-13 Alembic Limited A process for the preparation of amorphous form of rabeprazole sodium
CN102140099A (zh) 2010-02-02 2011-08-03 山东轩竹医药科技有限公司 新的吡啶衍生物
US9085556B2 (en) 2010-03-31 2015-07-21 Ranbaxy Laboraotories Limited Salts of dexlansoprazole and their preparation
CN102219777B (zh) * 2010-04-19 2013-06-05 江苏豪森药业股份有限公司 制备雷贝拉唑钠的方法
CN101805327B (zh) * 2010-04-29 2012-11-21 郝志艳 一种雷贝拉唑钠化合物及其制法
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR20140113667A (ko) 2011-12-16 2014-09-24 아토픽스 테라퓨릭스 리미티드 호산구성 식도염의 치료를 위한 ｃｒｔｈ2 길항제 및 양성자 펌프 저해제의 조합
WO2013108068A1 (en) 2012-01-21 2013-07-25 Jubilant Life Sciences Limited Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers
WO2014091450A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Process for the preparation of rabeprazole
CA2898362C (en) 2013-01-15 2020-09-01 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
CN103073536B (zh) * 2013-01-17 2015-06-24 丽珠医药集团股份有限公司 一种艾普拉唑的制备方法
CN103709141A (zh) * 2013-10-14 2014-04-09 寿光富康制药有限公司 雷贝拉唑钠的晶型及无定形形式
CN104119315B (zh) * 2014-05-21 2016-03-02 丽珠医药集团股份有限公司 一种雷贝拉唑钠的制备方法
RU2554735C1 (ru) * 2014-08-20 2015-06-27 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция, содержащая рабепразол натрия, и способ ее получения
US20180015118A1 (en) 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN106083705A (zh) * 2016-06-14 2016-11-09 上药康丽（常州）药业有限公司 2‑羟甲基‑4‑（甲氧基丙氧基）‑3‑甲基吡啶盐酸盐的制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN106349220A (zh) * 2016-08-25 2017-01-25 岳阳正昊化学科技有限公司 一种右旋雷贝拉唑钠的纯化方法
WO2018057989A1 (en) 2016-09-24 2018-03-29 Washington University INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF
MX2022002949A (es) 2019-09-24 2022-04-06 Prolacta Bioscience Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias e inmunes.
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL66340A (en) * 1981-08-13 1986-08-31 Haessle Ab Pharmaceutical compositions comprising pyridylmethyl-thiobenzimidazole derivatives,certain such novel derivatives and their preparation
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
GB8417171D0 (en) * 1984-07-05 1984-08-08 Beecham Group Plc Compounds
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds
DE3509333A1 (de) * 1985-03-15 1986-09-18 Hoechst Ag, 6230 Frankfurt Substituierte benzimidazolderivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer
JPH0674272B2 (ja) * 1986-11-13 1994-09-21 エーザイ株式会社 ピリジン誘導体及びそれを含有する潰瘍治療剤
DE4036908A1 (de) * 1990-11-20 1992-05-21 Ruetgers Pagid Ag Nutausbildung

Also Published As

Publication number Publication date
DE3752167D1 (de) 1998-03-12
DK131893A (da) 1993-11-24
JP2544567B2 (ja) 1996-10-16
LU90396I2 (fr) 1999-07-07
DK575887D0 (da) 1987-11-03
ES2061471T3 (es) 1994-12-16
JPH05247035A (ja) 1993-09-24
EP0475456B1 (en) 1998-02-04
DK131893D0 (da) 1993-11-24
DE19975035I2 (de) 2004-01-29
EP0654471B1 (en) 1998-07-08
US5045552A (en) 1991-09-03
HU198475B (en) 1989-10-30
KR910003330B1 (ko) 1991-05-27
FI90544C (fi) 1994-02-25
EP0475456A1 (en) 1992-03-18
US5998445A (en) 1999-12-07
NL990015I1 (nl) 1999-08-02
NZ222488A (en) 1993-05-26
NO874477D0 (no) 1987-10-27
ATE168111T1 (de) 1998-07-15
NO2000006I1 (no) 2000-09-18
DE3789536D1 (de) 1994-05-11
ES2112260T3 (es) 1998-04-01
NO170932C (no) 1992-12-30
AU8113887A (en) 1988-05-19
CA1265138A (en) 1990-01-30
NO874477L (no) 1988-05-16
HUT45524A (en) 1988-07-28
DE3752201T2 (de) 1998-12-17
DE3789536T2 (de) 1994-08-18
KR880006229A (ko) 1988-07-22
DE3752201D1 (de) 1998-08-13
AU594836B2 (en) 1990-03-15
EP0654471A1 (en) 1995-05-24
EP0268956B2 (en) 1998-04-15
HK194296A (en) 1996-11-01
ATE163011T1 (de) 1998-02-15
ES2061471T5 (es) 1998-07-16
FI874709L (fi) 1988-05-14
DK575887A (da) 1988-05-14
CN87107777A (zh) 1988-06-01
US5840910A (en) 1998-11-24
EP0268956A3 (en) 1990-07-25
NO170932B (no) 1992-09-21
FI874709A0 (fi) 1987-10-26
CN1018923B (zh) 1992-11-04
EP0268956A2 (en) 1988-06-01
EP0268956B1 (en) 1994-04-06
NL990015I2 (nl) 1999-09-01
DE3789536T3 (de) 1998-08-20
DK171024B1 (da) 1996-04-22
DE3752167T2 (de) 1998-06-25
FI90544B (fi) 1993-11-15

Similar Documents

Publication Publication Date Title
ES2112260T3 (es) Derivados de piridina, composiciones farmaceuticas que comprenden los mismos, su utilizacion en la fabricacion de medicamentos que tienen valor terapeutico o preventivo y procedimiento para su fabricacion.
ES2108425T3 (es) Analogos de atp sustituidos con n-alquilo-2.
ES2056190T3 (es) Derivados de 4(4-fenil-1-piperazinil)fenoles, inhibidores de 5-lipoxigenasa.
DK99584D0 (da) Salte af omeprazol, fremgangsmade til fremstilling deraf og anvendelse deraf
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
ES2031876T3 (es) Un procedimiento para la preparacion de 5,6-dihidro-2-(fenil sustituido)-1,2,4,-triazin-3,5(2h,4h)-dionas.
ES2054825T3 (es) Compuestos heterociclicos terapeuticos.
ES2123652T3 (es) 7-(2-aminoetil)-benzotiazolonas.
ES2080314T3 (es) Composiciones farmaceuticas.
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
ES2055523T3 (es) Agentes antifungicos de triazol.
ES2058527T3 (es) Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
FR2694004B1 (fr) Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
FI872864A0 (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
ES2123287T3 (es) Derivados 3-benzoil benzofuranicos como antagonistas de la hormona tiroidea.
ES8601965A1 (es) Un procedimiento para la preparacion de una nueva serie de derivados de (1-piperidinilalquil)pirimidinona
KR890700125A (ko) 신규 벤즈이미다졸 유도체, 그 제조방법 및 이 화합물을 함유하는 제약 조성물
ES2051843T3 (es) Un proceso para la preparacion de un derivado del acido benzoilaminofenoxibutanico.
ES2009723A4 (es) Derivados de acidos biliares, procedimientos para la preparacion de los mismos y composiciones farmaceuticas conteniendolos.
DK10488D0 (da) Benzen-derivater med antiinflammatorisk virkning og fremgangsmaade til fremstilling deraf
ATE165827T1 (de) Herstellung von n-acetylneuraminsäure-derivaten
ES2091183T3 (es) Metodo para mejorar el sueño.
SE8405588D0 (sv) New compounds
ES2055717T3 (es) Derivados de benzo- y tieno-3,4-dihidro-piridina, procedimientos para su preparacion y medicamentos que contienen estos compuestos.
GR880100159A (el) Μεθοδος παρασκευης φαρμακευτικων συνθεσεων.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 654471

Country of ref document: ES